Excerpt: CYDY) ( "CytoDyn" or the "Company" ), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced it has been selected for a poster and an oral presentation at the upcoming AACR Special Conference in Cancer Research:

The last presentation was poster only. Stepping up in the world?

https://www.cytodyn.com/newsroom/detail/645/c...conference